ABSTRACT
In this study, simple, rapid and accurate UV-Vis spectrophotometric method was developed for the determination ofcomplexes stoichiometry of Cu(II)-bupropion hydrochloride, Ca(II)-bupropion hydrochloride, Cd(II)-bupropionhydrochloride, Mg(II)-bupropion hydrochloride and Zn(II)-bupropion hydrochloride. The spectrums of the complexesformed between bupropion hydrochloride with Cu (II), Ca (II), Cd (II), Mg (II) and Zn (II) metal cations were taken in therange of 500 to 190 nm and the stoichiometry of the complexes formed between bupropion hydrochloride with Cu (II), Ca(II), Cd (II), Mg (II) and Zn (II) metal cations were determined by using the mole ratio method at maximum wavelength(λmax=252 nm). The stoichiometry of Cu(II)-bupropion hydrochloride, Ca(II)-bupropion hydrochloride, Cd(II)-bupropionhydrochloride and Zn(II)-bupropion hydrochloride were calculated as 1:1, but Mg(II)-bupropion hydrochloride complexwas calculated as 1:2. The recovery was found 95.0% for bupropion hydrochloride. Lambert-Beer’s obeyed theconcentration range of 1.40-6.91 µg/mL for bupropion hydrochloride. The LOD and LOQ were found to be 13.81 and 1.38µg/mL for bupropion hydrochloride, respectively. The interaction between bupropion hydrochloride with Cu (II), Ca (II), Cd(II), Mg (II) and Zn (II) were investigated by applying UV-visible spectrophotometric method, and satisfactory results wereobtained
ABSTRACT
OBJECTIVE@#To compare the clinical efficacy of acupoint catgut embedding and bupropion hydrochloride sustained-release tablets in the treatment of tobacco dependence.@*METHODS@#A total of 100 patients with tobacco dependence who met the inclusion criteria were randomly divided into an acupoint catgut embedding group and a drug group, 50 cases in each group. In the acupoint catgut embedding group, acupoint catgut embedding was applied at Xinshu (BL 15), Shenmen (HT 7), Tianmei (Extra), Taichong (LR 3), the treatment was given once every 2 weeks for 4 times; The bupropion hydrochloride sustained-release tablets was orally administered in the drug group for 7 weeks, 150 mg each time, once a day for the first 3 days, twice daily from day 4 to day 7, and once a day after day 8. The Fagerström test for nicotine dependence (FTND) score before and after treatment, the 4th and 8th week smoking cessation rate, the continuous smoking cessation rate and efficacy, compliance rate and adverse reaction rate were compared in the two groups.@*RESULTS@#A total of 100 patients were enrolled, and 97 patients completed the study (loss rate was 3%), including 49 cases in the acupoint catgut embedding group and 48 cases in the drug group. The FTND scores in the two groups were lower than those before treatment (both 0.05). At the 4th and the 8th week, the smoking cessation rate in the acupoint catgut embedding group was 40.8% (20/49) and 79.6% (39/49) respectively, the smoking cessation rate in the drug group was 41.7% (20/48) and 83.3% (40/48) respectively, the two groups were equally effective (both >0.05). The continuous smoking cessation rate in the acupoint embedding group was 40.8% (20/49), which was equivalent to 41.7% (20/48) in the drug group (>0.05). The rate of complete compliance in the acupoint embedding group was 61.2% (30/49), which was significantly better than 37.5% (18/48) in the drug group (<0.05). The adverse reaction rate in the acupoint catgut embedding group was 12.2% (6/49), which was significantly lower than 29.2% (16/48) in the drug group (<0.05).@*CONCLUSION@#Acupoint catgut embedding can effectively improve the symptoms of tobacco dependence after smoking cessation. Its curative effect is close to that of bupropion hydrochloride sustained-release tablets, and it has good clinical compliance and less adverse reactions.
Subject(s)
Humans , Acupuncture Points , Bupropion , Therapeutic Uses , Catgut , Delayed-Action Preparations , Tablets , Tobacco Use Disorder , TherapeuticsABSTRACT
0.05), CGI and HAMA. Safety analysis suggested that no significant differences were found in symptoms and frequency of side effects between the two groups.Conclusion Bupropion hydrochloride tablet is an effective and safe antidepressant. It has similar effect and safety compared with fluoxetine in the treatment of depression.